Results 171 to 180 of about 10,789 (224)

Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases?

Frontiers in Medicine, 2019
Thiopurines are a cheap, effective treatment option in the management of inflammatory bowel disease (IBD). However, with the growing choice of targeted therapies available, as well as the well-documented toxicities of thiopurines, the role of thiopurines
Sailish Honap, Peter M Irving
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Thiopurine toxicity

British Journal of Hospital Medicine, 2013
Thiopurines are a class of immunosuppressant and antineoplastic drugs developed by Gertrude Elion and George Hitchings and patented in 1953 for use to treat leukaemia, then used to prevent transplant rejection (Marx, 2005).
Kl, de Wit, Be, White, D, Goldsmith
openaire   +3 more sources

The thiopurines: An update

Investigational New Drugs, 2005
The thiopurine drugs, 6-mercaptopurine (6-MP), 6-thioguanine (6-TG) are commonly used cytotoxic agents. A derivative of 6-MP, azathioprine, is commonly used as an immunosuppressant. A prominent route for the metabolism of these agents is mediated by the enzyme thiopurine methyltransferase (TPMT).
Sally, Coulthard, Linda, Hogarth
openaire   +2 more sources

The Clinical Impact of Thiopurine Methyltransferase Polymorphisms on Thiopurine Treatment

Nucleosides, Nucleotides and Nucleic Acids, 2004
Acute lymphoblastic leukaemia (ALL) is the most common malignancy of childhood. Although current treatment results in long term survival in over 70% of cases there is evidence that as many as 50% could have been cured using a less complex regimen with a lower incidence of long term side effects.
S A, Coulthard, E C, Matheson, A G, Hall, L A, Hogarth   +3 more
openaire   +2 more sources

Individualization of Thiopurine Therapy: Thiopurine S -Methyltransferase and Beyond

Pharmacogenomics, 2009
The metabolism of a given drug depends, not solely on a particular enzyme, but rather on a complex metabolic network. Thiopurine S-methyltransferase (TPMT) catalyzes the methylation, and thus deactivation, of 6-mercaptopurine, a thiopurine used in the treatment of acute lymphoblastic leukemia.
Natasa, Karas-Kuzelicki, Irena, Mlinaric-Rascan   +1 more
openaire   +2 more sources

Thiopurine Methyltransferase and Thiopurine Metabolite Testing in Patients with Inflammatory Bowel Disease who are Taking Thiopurine Drugs

Pharmacogenomics, 2009
Thiopurine methyltransferase genotyping and thiopurine metabolite testing has been established as an adjunct to monitoring patients taking thiopurine drugs. This special report describes the clinical implications for this type of testing for patients with inflammatory bowel disease who are taking thiopurine drugs.
Leslie J, Sheffield, Peter, Irving, Arun, Gupta, Keith, Byron, Finlay A, Macrae, Hazel, Phillimore, Mithilesh, Dronavalli, Rosemary, Rose, Peter, George, Trevor, Walmsley, Barbara, Dixon, Susan, Poole, Michael, Dooley, Miles, Sparrow   +13 more
openaire   +2 more sources

The Effect of Thiopurine Methyltransferase Expression on Sensitivity to Thiopurine Drugs

Molecular Pharmacology, 2002
Although the thiopurine drugs 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are well established agents for the treatment of leukemia, controversies remain regarding their main mode of action. Previous evidence has suggested that although 6-TG exerts a cytotoxic effect through incorporation of 6-thioguanine nucleotides into newly synthesized DNA ...
Coulthard, S.A., Hogarth, L.A., Little, M.A., Matheson, E., Redfern, C.P.F., Minto, C.L.J., Hall, A.G.   +13 more
openaire   +3 more sources

Pharmacogenetics of Thiopurine S-Methyltransferase and Thiopurine Therapy

Therapeutic Drug Monitoring, 2004
Most medications exhibit wide interpatient variability in their efficacy and toxicity. For many medications, these interindividual differences result in part from polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters, and/or drug targets (eg, receptors, enzymes).
openaire   +2 more sources

Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease

Digestive and Liver Disease, 2018
To assess the utility and tolerability of thiopurine-allopurinol co-therapy in inflammatory bowel disease (IBD) patients with intolerance to thiopurine monotherapy.A retrospective observational study assessed cases of thiopurine intolerance then switched to thiopurine allopurinol co-therapy between 2011 and 2015 at two centres.
Abhinav Vasudevan, Lauren Beswick, Antony B. Friedman, Alicia Moltzen, James Haridy, Ajay Raghunath, Miles Sparrow, Daniel van Langenberg   +7 more
openaire   +2 more sources